Related Content
- Mylan to launch educational site about generic drugs
- FDA opens dialogue of incorporating technology, pharmacy into switch paradigm
- New alliance will crack down on adulterated products touting dietary supplement claims
- Sandoz announces FDA approval, U.S. launch of chemotherapy drug
- Mylan's Hyzaar, Cozaar generics receive OK from FDA
PITTSBURGH — The Food and Drug Administration has approved a generic drug for motion sickness made by Mylan.
The drug maker announced Friday that the FDA had approved meclizine hydrochloride tablets in the 12.5-mg, 25-mg and 50-mg strengths. Mylan said it would launch the drug immediately.
The drug is a generic version of Pfizer's Antivert, which is used to treat nausea, vomiting and dizziness associated with motion sickness. Antivert had sales of about $53.5 million during the 12-month period ended in June, according to IMS Health.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
